Form D · Biotechnology

Theranos Inc

Palo Alto, CA · CIK 0001313697

Offering snapshot reported May 30, 2017 · SEC filing

Reported sold
$582M
Offering amount: $582M
Investors reported
34
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 15, 2017
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 30, 2017Initial$582,200,318No comparison34SEC filing
Jul 8, 2010Initial$45,000,000No comparison1SEC filing
Nov 17, 2006PaperNot reportedNo comparisonNot reportedSEC filing
Feb 21, 2006PaperNot reportedNo comparisonNot reportedSEC filing
Jan 3, 2005PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-287627
Total offering amount represents the aggregate original issue price of the securities tendered in the Issuer's exchange offer with existing holders of its preferred stock.

Source: Form D, filed May 30, 2017. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Ramesh Balwani Director, Executive
Fabrizio Bonanni Director
William Foege Director
Elizabeth Anne Holmes Director, Executive
Donald L Lucas Director
Channing Robertson Director
Robert Shapiro Director
T. Peter Thomas Director
Daniel Warmenhoven Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1701 Page Mill Road
Palo Alto, CA, 94304